As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
19 Analysts have issued a Ocular Therapeutix Inc forecast:
19 Analysts have issued a Ocular Therapeutix Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 56 56 |
9%
9%
|
|
| Gross Profit | 50 50 |
11%
11%
|
|
| EBITDA | -247 -247 |
80%
80%
|
|
| EBIT (Operating Income) EBIT | -251 -251 |
78%
78%
|
|
| Net Profit | -250 -250 |
43%
43%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
| Head office | United States |
| CEO | Pravin Dugel |
| Employees | 274 |
| Founded | 2006 |
| Website | www.ocutx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


